Verify claims against the facility that will actually handle the medicine. FDA states that outsourcing registration and inspections are facility-specific; registration does not establish product approval or compliance with all applicable requirements. FDA registration Q&A.
What belongs in the evidence register?
Use these columns:
Claim | Product/route | Legal entity | Facility | State | Source/document | Source date | Checked date | Evidence status | Reviewer | Open question | Deadline | Decision impact
Recommended evidence statuses are independently verified, supplier-supported but not independently confirmed, missing, adverse evidence requiring assessment, and not applicable.
| Check | Independent action | Suggested procurement response to a gap |
|---|---|---|
| Entity identity | Match legal names and addresses across contracts, licences and actual fulfilment documents | Resolve mismatches before routing |
| Pharmacy permissions | Search the home-state and destination-state boards | Exclude unverified states from launch |
| 503B registration, if relevant | Check FDA's register for the precise facility | Do not use a corporate-group entry as a substitute |
| Inspection and enforcement history | Search FDA compounding actions, warning letters and state records | Obtain responses and qualified interpretation |
| Corrective actions | Request evidence supporting closure or effectiveness | Do not accept a promise of future remediation as completed work |
| Product provenance | Reconcile seller, source, product identifier and lot documentation | Escalate unexplained supply-chain breaks |
| Storage and transport | Review product-specific handling and shipping qualification evidence | Require a documented excursion process |
| Recall readiness | Run a tabletop exercise connecting product/lot to affected orders | Fix missing traceability before scale |
Useful primary-source starting points are FDA's registered outsourcing facilities, compounding inspections and actions, and wholesale-distributor reporting information. The outsourcing register reviewed here was updated November 6, 2026; preserve that source date alongside your own review date.
How should you interpret an FDA Form 483?
A Form 483 records inspection observations; it is not a final agency determination of a violation. FDA considers it together with the inspection report, evidence and company responses. Request the complete sequence and have a qualified reviewer assess relevance to the proposed supply. FDA Form 483 FAQ.
Conversely, do not turn an unsuccessful public-record search into a positive quality conclusion. Record exactly what was searched and what remains unavailable.
Why does “nationwide pharmacy coverage” need checking?
Build a facility-by-state matrix rather than accepting a national marketing claim. California, for example, requires the relevant nonresident sterile-compounding licence for a nonresident pharmacy compounding sterile products for shipment into the state. Texas distinguishes nonresident pharmacy requirements and states that a delinquent licence requires cessation of shipping prescriptions into Texas until active status is restored. California pharmacy lawbook; Texas nonresident requirements.
Use one row per actual fulfilling location and destination:
Facility | Destination | Required permission | Licence/status | Expiry | Product accepted | Capacity confirmed | Delivery tested | Launch decision
Keep prescriber authorisation and telehealth requirements in a separate legal workstream; pharmacy coverage is not the same question.
What should you do about DSCSA?
Ask counsel to map responsibilities to each party's actual supply-chain role and transaction. FDA's current exemption page extends certain requirements for qualifying small dispensers to November 27, 2027. Its definition uses the owning company's pharmacist/pharmacy-technician employee count as of November 27, 2026—not the clinic's number of prescribers. This is not an exemption from every DSCSA obligation. FDA exemptions. (fda.gov)
Request a written responsibility matrix covering trading-partner verification, applicable transaction records, suspect-product handling, recall support and record access. For any claimed exemption, retain its scope, basis and expiration.
How should you evaluate cold chain, packaging and dosing instructions?
Use the exact presentation's current label and the supplier's qualified procedures—not a generic GLP-1 temperature rule. For example, Zepbound's prescribing information has presentation-specific storage instructions and prohibits use after freezing. Current prescribing information.
For any compounded preparation that survives eligibility review, obtain independent clinical/pharmacy review of concentration, volume, labelled instructions, supplied measuring device and patient education. FDA has reported dosing errors involving varying concentrations and confusion among milligrams, millilitres and syringe units. FDA dosing-error alert.
Do not equate a certificate of analysis with complete assurance about the finished preparation, patient instructions or distribution process. Treat it as one item in a broader quality review.
Stage 4 exit document: an accepted evidence register and a launch matrix that identifies unsupported states, products or facilities explicitly.
Explore the table row by row
A working view of the research
Entity identity
- Independent action
- Match legal names and addresses across contracts, licences and actual fulfilment documents
- Suggested procurement response to a gap
- Resolve mismatches before routing
Answers stay in this session unless you choose to save. No account needed.
Sources cited on this page
- fda.gov · Source 1 ↗https://www.fda.gov/drugs/human-drug-compounding/questions-and-answers-outsourcing-facility-registration
- fda.gov · Source 2 ↗https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities
- fda.gov · Source 3 ↗https://www.fda.gov/drugs/human-drug-compounding/compounding-inspections-recalls-and-other-actions
- fda.gov · Source 4 ↗https://www.fda.gov/drugs/drug-supply-chain-security-act/annual-reporting-prescription-drug-wholesale-distributors-and-third-party-logistics-providers
- fda.gov · Source 5 ↗https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-references/fda-form-483-frequently-asked-questions
- pharmacy.ca.gov · Source 6 ↗https://www.pharmacy.ca.gov/laws_regs/lawbook
- pharmacy.texas.gov · Source 7 ↗https://www.pharmacy.texas.gov/licensees/nonresident-pharmacy-requirements.asp
- fda.gov · Source 8 ↗https://www.fda.gov/drugs/drug-supply-chain-security-act-dscsa/exemptions-under-drug-supply-chain-security-act
- uspl.lilly.com · Source 9 ↗https://uspl.lilly.com/zepbound/zepbound.html
- fda.gov · Source 10 ↗https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded